Oncgnostics Cervical Cancer Assay Receives Extended CE-IVD Mark

Feb 26, 2019

|

NEW YORK (GenomeWeb) – Oncgnostics announced recently that it has received an extended CE-IVD mark for the GynTect cervical cancer assay. As a result, researchers can run the assay on Roche Diagnostics' Cobas z 480 quantitative PCR-based analyzer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Oncgnostics Cervical Cancer Assay Receives Extended CE-IVD Mark

To read the full story....

Breaking News

Hologic Fiscal Q1 Revenues Rise 89 Percent as Dx Testing Demand Surges

Spectrum Solutions, UCLA Partner to Study Saliva-Based Early-Stage Lung Cancer Detection

T2 Biosystems Preliminary Q4 Revenues Grow 155 Percent, Miss Estimates

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Siemens Healthineers Q1 Diagnostics Revenues Rise 17 Percent on Pandemic-Related Demand

Abbott Panbio SARS-CoV-2 Rapid Antigen Test Nabs CE Mark for Asymptomatic Screening, Self-Collection

Featured White Papers

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

What's Popular?

Spectrum Solutions, UCLA Partner to Study Saliva-Based Early-Stage Lung Cancer Detection

NeoGenomics to Grow Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit

OncoLab Diagnostics Targets Cancer Recurrence Monitoring with CTC-Derived Biomarker Assay

Todos Medical Obtains $3.4M Investment From Yozma Group Korea

Sponsorships